RKV Stock Overview
Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi).
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rakovina Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.09 |
| 52 Week High | CA$0.16 |
| 52 Week Low | CA$0.005 |
| Beta | 0.19 |
| 1 Month Change | 28.57% |
| 3 Month Change | -10.00% |
| 1 Year Change | -37.93% |
| 3 Year Change | -47.06% |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Shareholder Returns
| RKV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 12.5% | -6.4% | -2.1% |
| 1Y | -37.9% | -35.6% | 3.6% |
Return vs Industry: RKV underperformed the Canadian Biotechs industry which returned -33.7% over the past year.
Return vs Market: RKV underperformed the Canadian Market which returned 3.2% over the past year.
Price Volatility
| RKV volatility | |
|---|---|
| RKV Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: RKV's share price has been volatile over the past 3 months.
Volatility Over Time: RKV's weekly volatility has decreased from 24% to 18% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mads Daugaard | www.rakovinatherapeutics.com |
Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi). Its preclinical product pipeline include kt-2000, a next generation oral targeted small molecule PARP inhibitors; kt-3000, a bi-functional small-molecule drug candidate; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.
Rakovina Therapeutics Inc. Fundamentals Summary
| RKV fundamental statistics | |
|---|---|
| Market cap | CA$6.66m |
| Earnings (TTM) | -CA$2.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs RKV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RKV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.54m |
| Earnings | -CA$2.54m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 30.4% |
How did RKV perform over the long term?
See historical performance and comparison